Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?

Ann Oncol. 2021 Feb;32(2):279-280. doi: 10.1016/j.annonc.2020.10.602. Epub 2020 Dec 9.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Humans
  • Immunotherapy
  • Ipilimumab / therapeutic use
  • Melanoma* / diagnostic imaging
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Mutation
  • Nivolumab / therapeutic use
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use

Substances

  • Ipilimumab
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Nivolumab
  • olaparib